Peripheral arterial disease (PAD) is a highly prevalent atherosclerotic condition. In patients
with PAD, the presence of intermittent claudication leads to a deterioration in quality of life. In …

Background: Secondary prevention lifestyle and pharmacological treatment of
atherosclerotic cardiovascular disease (ASCVD) reduce a high proportion of recurrent …

Background Regularity and continuity of general practitioner (GP) contacts are associated
with reduced hospitalisation. Opportunities for improved medication management are cited …

Background Patients with intermittent claudication need lifelong treatment with secondary
prevention to prevent cardiovascular events and progression of atherosclerotic disease …

Background: Sex-related differences may influence the outcome of endovascular
revascularization (EVR) in patients with lower extremity arterial disease (LEAD) even under …

Introduction: Antiplatelet therapy needs to be administered life-long in patients with
peripheral arterial disease (PAD). Our study was aimed at 1) the analysis of non-persistence …

Introduction The benefit of secondary prevention in hypertensive patients with peripheral
arterial disease (PAD) is based on continual simultaneous taking of statins, antiplatelet …

Objectives Adherence to peripheral arterial disease (PAD) treatment remains low, despite its
benefit for secondary disease prevention. Currently, there is no qualitative research …

Objective Adherence to peripheral artery disease (PAD) treatment reduces the risk of
cardiovascular events and delays disease progression, but patients do not fully adhere to …

The effectiveness of statins in secondary prevention of peripheral arterial disease (PAD)
largely depends on patients' adherence to treatment. The aims of our study were:(a) to …